Pub Date : 2023-11-23DOI: 10.1016/j.survophthal.2023.11.005
Jasmine Yaowei Ge , Zhen Ling Teo , Miao Li Chee , Yih-Chung Tham , Tyler Hyungtaek Rim , Ching-Yu Cheng , Tien Yin Wong , SNEC Surgical Retina Research Group , Edmund Yick Mun Wong , Shu Yen Lee , Ning Cheung
We set out to estimate the international incidence of rhegmatogenous retinal detachment (RRD) and to evaluate its temporal trend over time. There is a lack of robust estimates on the worldwide incidence and trend for RRD, a major cause of acute vision loss. We conducted a systematic review of RRD incidence. The electronic databases PubMed, Scopus, and Thomson Reuters’ Web of Science were searched from inception through 2nd June 2022. Random-effects meta-analysis model with logit transformation was performed to obtain pooled annual incidence estimates of RRD. Pooled analysis was performed to evaluate the temporal trend of RRD incidence of the 20,958 records identified from the database searches; 33 studies from 21 countries were included for analysis (274,836 cases of RRD in 273,977 persons). Three of the 6 global regions as defined by WHO had studies that met the inclusion and exclusion criteria of the study. The annual international incidence of RRD was estimated to be 12.17 (95% confidence interval [CI] 10.51–14.09) per 100,000 population; with an increasing temporal trend of RRD at 5.4 per 100,000 per decade (p 0.001) from 1997 to 2019. Amongst world regions, the RRD incidence was highest in Europe (14.52 [95% CI 11.79 – 17.88] per 100,000 population), followed by Western Pacific (10.55 [95% CI 8.71–12.75] per 100,000 population) and Regions of Americas (8.95 [95% CI 6.73–11.92] per 100,000 population). About one in 10,000 persons develop RRD each year. There is evidence of increasing trend for RRD incidence over time, with possibly doubling of the current incidence rate within the next 2 decades.
我们着手估计国际上孔源性视网膜脱离(RRD)的发病率,并评估其随时间的时间趋势。RRD是急性视力丧失的一个主要原因,目前缺乏对其全球发病率和趋势的可靠估计。我们对RRD发病率进行了系统回顾。电子数据库PubMed、Scopus和Thomson Reuters的Web of Science从创建到2022年6月2日进行了搜索。采用logit变换的随机效应荟萃分析模型获得RRD的合并年发病率估计值。采用合并分析评估RRD发病率的时间趋势。在从数据库检索中确定的20,958条记录中,包括来自21个国家的33项研究进行分析(273,977人中的274,836例RRD)。在世卫组织定义的6个全球区域中,有3个区域的研究符合该研究的纳入和排除标准。据估计,每年RRD的国际发病率为每10万人12.17例(95%可信区间[CI] 10.51-14.09);RRD的时间增长趋势为每10年每10万人中有5.4人
{"title":"International incidence and temporal trends for rhegmatogenous retinal detachment: A systematic review and meta-analysis","authors":"Jasmine Yaowei Ge , Zhen Ling Teo , Miao Li Chee , Yih-Chung Tham , Tyler Hyungtaek Rim , Ching-Yu Cheng , Tien Yin Wong , SNEC Surgical Retina Research Group , Edmund Yick Mun Wong , Shu Yen Lee , Ning Cheung","doi":"10.1016/j.survophthal.2023.11.005","DOIUrl":"10.1016/j.survophthal.2023.11.005","url":null,"abstract":"<div><p>We set out to estimate the international incidence of rhegmatogenous retinal detachment<span><span> (RRD) and to evaluate its temporal trend over time. There is a lack of robust estimates on the worldwide incidence and trend for RRD, a major cause of acute vision loss. We conducted a </span>systematic review of RRD incidence. The electronic databases PubMed, Scopus, and Thomson Reuters’ Web of Science were searched from inception through 2nd June 2022. Random-effects meta-analysis model with logit transformation was performed to obtain pooled annual incidence estimates of RRD. Pooled analysis was performed to evaluate the temporal trend of RRD incidence of the 20,958 records identified from the database searches; 33 studies from 21 countries were included for analysis (274,836 cases of RRD in 273,977 persons). Three of the 6 global regions as defined by WHO had studies that met the inclusion and exclusion criteria of the study. The annual international incidence of RRD was estimated to be 12.17 (95% confidence interval [CI] 10.51–14.09) per 100,000 population; with an increasing temporal trend of RRD at 5.4 per 100,000 per decade (p 0.001) from 1997 to 2019. Amongst world regions, the RRD incidence was highest in Europe (14.52 [95% CI 11.79 – 17.88] per 100,000 population), followed by Western Pacific (10.55 [95% CI 8.71–12.75] per 100,000 population) and Regions of Americas (8.95 [95% CI 6.73–11.92] per 100,000 population). About one in 10,000 persons develop RRD each year. There is evidence of increasing trend for RRD incidence over time, with possibly doubling of the current incidence rate within the next 2 decades.</span></p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138435113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-23DOI: 10.1016/j.survophthal.2023.11.003
Sayena Jabbehdari , Anthony C. Oganov , Fateme Rezagholi , Soheil Mohammadi , Hamid Harandi , Ghasem Yazdanpanah , J. Fernando Arevalo
Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in the elderly, and neurodegenerative disorders such as Alzheimer disease and Parkinson disease are debilitating conditions that affect millions worldwide. Despite the different clinical manifestations of these diseases, growing evidence suggests that they share common pathways in their pathogenesis including inflammation, oxidative stress, and impaired autophagy. In this review, we explore the complex interactions between AMD and neurodegenerative disorders, focusing on their shared mechanisms and potential therapeutic targets. We also discuss the current opportunities and challenges for developing effective treatments that can target these pathways to prevent or slow down disease progression in AMD. Some of the promising strategies that we explore include modulating the immune response, reducing oxidative stress, enhancing autophagy and lysosomal function, and targeting specific protein aggregates or pathways. Ultimately, a better understanding of the shared pathways between AMD and neurodegenerative disorders may pave the way for novel and more efficacious treatments.
{"title":"Age-related macular degeneration and neurodegenerative disorders: Shared pathways in complex interactions","authors":"Sayena Jabbehdari , Anthony C. Oganov , Fateme Rezagholi , Soheil Mohammadi , Hamid Harandi , Ghasem Yazdanpanah , J. Fernando Arevalo","doi":"10.1016/j.survophthal.2023.11.003","DOIUrl":"10.1016/j.survophthal.2023.11.003","url":null,"abstract":"<div><p><span>Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in the elderly, and </span>neurodegenerative disorders<span> such as Alzheimer disease and Parkinson disease<span> are debilitating conditions that affect millions worldwide. Despite the different clinical manifestations of these diseases, growing evidence suggests that they share common pathways in their pathogenesis including inflammation, oxidative stress<span>, and impaired autophagy. In this review, we explore the complex interactions between AMD and neurodegenerative disorders, focusing on their shared mechanisms and potential therapeutic targets. We also discuss the current opportunities and challenges for developing effective treatments<span> that can target these pathways to prevent or slow down disease progression in AMD. Some of the promising strategies that we explore include modulating the immune response, reducing oxidative stress, enhancing autophagy and lysosomal function, and targeting specific protein aggregates or pathways. Ultimately, a better understanding of the shared pathways between AMD and neurodegenerative disorders may pave the way for novel and more efficacious treatments.</span></span></span></span></p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138435112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-23DOI: 10.1016/j.survophthal.2023.11.007
Francesco Pellegrini , Maria Basciu , Rod Foroozan
A 63-year-old man with diabetes presented with unilateral ptosis and an exotropia. A diagnosis of isolated diabetic III nerve palsy was made. Subsequent neuro-ophthalmologic evaluation showed multiple cranial nerves involvement consistent with a diagnosis of orbital apex syndrome. Review of past medical history was significant for a previous nasopharyngeal carcinoma, and biopsy of the involved site was consistent with tumor recurrence. This case highlights the importance of correct medical history taking and anatomo-clinical correlation in neuro-ophthalmology.
{"title":"Planet of the apex","authors":"Francesco Pellegrini , Maria Basciu , Rod Foroozan","doi":"10.1016/j.survophthal.2023.11.007","DOIUrl":"10.1016/j.survophthal.2023.11.007","url":null,"abstract":"<div><p>A 63-year-old man with diabetes presented with unilateral ptosis<span><span><span> and an exotropia<span>. A diagnosis of isolated diabetic III nerve palsy was made. Subsequent neuro-ophthalmologic evaluation showed multiple cranial nerves involvement consistent with a diagnosis of </span></span>orbital apex syndrome<span>. Review of past medical history<span> was significant for a previous nasopharyngeal carcinoma<span>, and biopsy of the involved site was consistent with tumor recurrence. This case highlights the importance of correct </span></span></span></span>medical history taking and anatomo-clinical correlation in neuro-ophthalmology.</span></p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138441297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-04DOI: 10.1016/j.survophthal.2023.09.002
Bhim B. Rai PhD , Joshua P. van Kleef PhD , Faran Sabeti PhD , Robin Vlieger PhD , Hanna Suominen PhD , Ted Maddess PhD
It is now clear that retinal neuropathy precedes classical microvascular retinopathy in diabetes. Therefore, tests that underpin useful new endpoints must provide high diagnostic power well before the onset of moderate diabetic retinopathy. Hence, we compare detection methods of early diabetic eye damage. We reviewed data from a range of functional and structural studies of early diabetic eye disease and computed standardized effect size as a measure of diagnostic power, allowing the studies to be compared quantitatively. We then derived minimum performance criteria for tests to provide useful clinical endpoints. This included the criteria that tests should be rapid and easy so that children with type 1 diabetes can be followed into adulthood with the same tests. We also defined attributes that lend test data to further improve performance using Machine/Deep Learning. Data from a new form of objective perimetry suggested that the criteria are achievable.
{"title":"Early diabetic eye damage: Comparing detection methods using diagnostic power","authors":"Bhim B. Rai PhD , Joshua P. van Kleef PhD , Faran Sabeti PhD , Robin Vlieger PhD , Hanna Suominen PhD , Ted Maddess PhD","doi":"10.1016/j.survophthal.2023.09.002","DOIUrl":"10.1016/j.survophthal.2023.09.002","url":null,"abstract":"<div><p>It is now clear that retinal neuropathy precedes classical microvascular retinopathy in diabetes. Therefore, tests that underpin useful new endpoints must provide high diagnostic power well before the onset of moderate diabetic retinopathy. Hence, we compare detection methods of early diabetic eye damage. We reviewed data from a range of functional and structural studies of early diabetic eye disease and computed standardized effect size as a measure of diagnostic power, allowing the studies to be compared quantitatively. We then derived minimum performance criteria for tests to provide useful clinical endpoints. This included the criteria that tests should be rapid and easy so that children with type 1 diabetes can be followed into adulthood with the same tests. We also defined attributes that lend test data to further improve performance using Machine/Deep Learning. Data from a new form of objective perimetry suggested that the criteria are achievable.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0039625723001145/pdfft?md5=3419c8eaf727102585ca7ee0c9a51f1f&pid=1-s2.0-S0039625723001145-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41152020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-29DOI: 10.1016/j.survophthal.2023.09.006
Alexis Ceecee Britten-Jones BOptom (Hons), PhD , Lawrence Thai BBiomed , Jeremy P.M. Flanagan BSc (Hons), GCTE , Phillip A. Bedggood BOptom, PhD , Thomas L. Edwards PhD, FRANZCO , Andrew B. Metha BOptom, PhD , Lauren N. Ayton BOptom, PhD
Adaptive optics (AO) imaging enables direct, objective assessments of retinal cells. Applications of AO show great promise in advancing our understanding of the etiology of inherited retinal disease (IRDs) and discovering new imaging biomarkers. This scoping review systematically identifies and summarizes clinical studies evaluating AO imaging in IRDs. Ovid MEDLINE and EMBASE were searched on February 6, 2023. Studies describing AO imaging in monogenic IRDs were included. Study screening and data extraction were performed by 2 reviewers independently. This review presents (1) a broad overview of the dominant areas of research; (2) a summary of IRD characteristics revealed by AO imaging; and (3) a discussion of methodological considerations relating to AO imaging in IRDs. From 140 studies with AO outcomes, including 2 following subretinal gene therapy treatments, 75% included fewer than 10 participants with AO imaging data. Of 100 studies that included participants’ genetic diagnoses, the most common IRD genes with AO outcomes are CNGA3, CNGB3, CHM, USH2A, and ABCA4. Confocal reflectance AO scanning laser ophthalmoscopy was the most reported imaging modality, followed by flood-illuminated AO and split-detector AO. The most common outcome was cone density, reported quantitatively in 56% of studies. Future research areas include guidelines to reduce variability in the reporting of AO methodology and a focus on functional AO techniques to guide the development of therapeutic interventions.
{"title":"Adaptive optics imaging in inherited retinal diseases: A scoping review of the clinical literature","authors":"Alexis Ceecee Britten-Jones BOptom (Hons), PhD , Lawrence Thai BBiomed , Jeremy P.M. Flanagan BSc (Hons), GCTE , Phillip A. Bedggood BOptom, PhD , Thomas L. Edwards PhD, FRANZCO , Andrew B. Metha BOptom, PhD , Lauren N. Ayton BOptom, PhD","doi":"10.1016/j.survophthal.2023.09.006","DOIUrl":"10.1016/j.survophthal.2023.09.006","url":null,"abstract":"<div><p>Adaptive optics (AO) imaging enables direct, objective assessments of retinal cells. Applications of AO show great promise in advancing our understanding of the etiology of inherited retinal disease (IRDs) and discovering new imaging biomarkers. This scoping review systematically identifies and summarizes clinical studies evaluating AO imaging in IRDs. Ovid MEDLINE and EMBASE were searched on February 6, 2023. Studies describing AO imaging in monogenic IRDs were included. Study screening and data extraction were performed by 2 reviewers independently. This review presents (1) a broad overview of the dominant areas of research; (2) a summary of IRD characteristics revealed by AO imaging; and (3) a discussion of methodological considerations relating to AO imaging in IRDs. From 140 studies with AO outcomes, including 2 following subretinal gene therapy treatments, 75% included fewer than 10 participants with AO imaging data. Of 100 studies that included participants’ genetic diagnoses, the most common IRD genes with AO outcomes are <em>CNGA3</em>, <em>CNGB3</em>, <em>CHM</em>, <em>USH2A</em>, and <em>ABCA4</em>. Confocal reflectance AO scanning laser ophthalmoscopy was the most reported imaging modality, followed by flood-illuminated AO and split-detector AO. The most common outcome was cone density, reported quantitatively in 56% of studies. Future research areas include guidelines to reduce variability in the reporting of AO methodology and a focus on functional AO techniques to guide the development of therapeutic interventions.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0039625723001297/pdfft?md5=389f41ff81fbc8b2825fc3eeb742568e&pid=1-s2.0-S0039625723001297-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41140349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-28DOI: 10.1016/j.survophthal.2023.09.007
Jerry Hsu MD , Jasmine H. Francis MD , Sumayya Ahmad MD
Fibroblast growth factor receptor (FGFR) inhibitors are an emerging class of small molecule targeted cancer drugs with promising therapeutic possibilities for a wide variety of malignancies. While ocular adverse events from FGFR inhibitors are reported in clinical trials, subsequent case studies continue to reveal new toxicities. Disease pathology affecting multiple parts of the eye has been reported, but the ocular surface and the retina are the most commonly encountered areas affected by FGFR inhibitors, manifesting as dry eye and FGFR inhibitor-associated retinopathy, respectively. Corneal thinning and melt is a rare but serious and potentially vision-threatening complication of FGFR inhibitor toxicity. Similarities between toxicities observed from other targeted cancer therapy drugs and FGFR inhibitors may help us understand underlying pathophysiological changes. The management of these adverse events requires close ophthalmologic follow-up and may require discontinuation of the offending agents in some cases.
{"title":"Ocular toxicities of fibroblast growth factor receptor inhibitors: A review","authors":"Jerry Hsu MD , Jasmine H. Francis MD , Sumayya Ahmad MD","doi":"10.1016/j.survophthal.2023.09.007","DOIUrl":"10.1016/j.survophthal.2023.09.007","url":null,"abstract":"<div><p><span><span>Fibroblast growth factor receptor (FGFR) inhibitors are an emerging class of small molecule targeted cancer </span>drugs<span> with promising therapeutic possibilities for a wide variety of malignancies. While ocular adverse events from FGFR inhibitors are reported in </span></span>clinical trials<span>, subsequent case studies continue to reveal new toxicities. Disease pathology affecting multiple parts of the eye has been reported, but the ocular surface<span> and the retina are the most commonly encountered areas affected by FGFR inhibitors, manifesting as dry eye and FGFR inhibitor-associated retinopathy<span>, respectively. Corneal thinning and melt is a rare but serious and potentially vision-threatening complication of FGFR inhibitor toxicity. Similarities between toxicities observed from other targeted cancer therapy drugs and FGFR inhibitors may help us understand underlying pathophysiological changes. The management of these adverse events requires close ophthalmologic follow-up and may require discontinuation of the offending agents in some cases.</span></span></span></p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41150063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-27DOI: 10.1016/j.survophthal.2023.09.005
Francesco D’Oria MD , Simone A. Bagaglia MD , Jorge L. Alio del Barrio MD, PhD, FEBOS-CR , Giovanni Alessio MD, PhD , Jorge L. Alio MD, PhD, FEBO , Cosimo Mazzotta MD, PhD
Keratoconus is an ectatic corneal disorder that causes severe vision loss. Surgical options allow us to correct, partially or totally, the induced refractive error. Intracorneal ring segments (ICRS) implantation represents a minimally invasive surgical option that improves visual acuity, with a high success rate and a low overall complication rate. Corneal allogenic ICRS consists of ring segments derived from allogenic eye bank-processed donor corneas. Selective topography-guided transepithelial photorefractive or phototherapeutic keratectomy combined with CXL is another way in selected cases to improve spectacles corrected distance visual acuity. The microphotoablative remodeling of the central corneal profile is generally planned by optimizing the optical zones and minimizing tissue consumption. Phakic intraocular lens (PIOL) implant is considered in patients with stable disease and acceptable anatomical requirements. The two types of pIOLs, depending on their implantation inside the eye, are anterior chamber-pIOLs, which fixate to the anterior surface of the iris by using a polymethomethacrolate claw at the two haptics, and posterior chamber-pIOLs. In patients with both cataracts and keratoconus, the correct IOL power is difficult to obtain due to the irregular corneal shape and K values. Toric IOL is recommended, but carefully judging the topography and the possible need of subsequent keratoplasties.
{"title":"Refractive surgical correction and treatment of keratoconus","authors":"Francesco D’Oria MD , Simone A. Bagaglia MD , Jorge L. Alio del Barrio MD, PhD, FEBOS-CR , Giovanni Alessio MD, PhD , Jorge L. Alio MD, PhD, FEBO , Cosimo Mazzotta MD, PhD","doi":"10.1016/j.survophthal.2023.09.005","DOIUrl":"10.1016/j.survophthal.2023.09.005","url":null,"abstract":"<div><p>Keratoconus is an ectatic corneal disorder that causes severe vision loss. Surgical options allow us to correct, partially or totally, the induced refractive error. Intracorneal ring segments (ICRS) implantation represents a minimally invasive surgical option that improves visual acuity, with a high success rate and a low overall complication rate. Corneal allogenic ICRS consists of ring segments derived from allogenic eye bank-processed donor corneas. Selective topography-guided transepithelial photorefractive or phototherapeutic keratectomy combined with CXL is another way in selected cases to improve spectacles corrected distance visual acuity. The microphotoablative remodeling of the central corneal profile is generally planned by optimizing the optical zones and minimizing tissue consumption. Phakic intraocular lens (PIOL) implant is considered in patients with stable disease and acceptable anatomical requirements. The two types of pIOLs, depending on their implantation inside the eye, are anterior chamber-pIOLs, which fixate to the anterior surface of the iris by using a polymethomethacrolate claw at the two haptics, and posterior chamber-pIOLs. In patients with both cataracts and keratoconus, the correct IOL power is difficult to obtain due to the irregular corneal shape and K values. Toric IOL is recommended, but carefully judging the topography and the possible need of subsequent keratoplasties.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S003962572300125X/pdfft?md5=ee57a6f457573dda063efd2a04a8003e&pid=1-s2.0-S003962572300125X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41171663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-27DOI: 10.1016/j.survophthal.2023.09.004
Ikhwanuliman Putera MD , Asri Salima Ridwan MD , Metta Dewi MD , Carlos Cifuentes-González MD , William Rojas-Carabali MD , Ratna Sitompul MD, PhD , Lukman Edwar MD, PhD , Made Susiyanti MD, PhD , Yulia Aziza MD, PhD , Carlos Pavesio MD, PhD , Soon-Phaik Chee MD , Padmamalini Mahendradas DO, DNB , Jyotirmay Biswas MS , John H. Kempen MD, MPH, PhD, MHS , Vishali Gupta MD , Alejandra de-la-Torre MD, PhD , Rina La Distia Nora MD, PhD , Rupesh Agrawal MD, FRCS
Acute retinal necrosis is a progressive intraocular inflammatory syndrome characterized by diffuse necrotizing retinitis that can lead to a poor visual outcome, mainly from retinal detachment. The antiviral treatment approach for acute retinal necrosis varies as there are no established guidelines. We summarize the outcomes of acute retinal necrosis with available antiviral treatments. Electronic searches were conducted in PubMed/MEDLINE, EMBASE, Scopus, and Google Scholar for interventional and observational studies. Meta-analysis was performed to evaluate the pooled proportion of the predefined selected outcomes. This study was registered in PROSPERO (CRD42022320987). Thirty-four studies with a total of 963 participants and 1,090 eyes were included in the final analysis. The estimated varicella-zoster virus and herpes simplex virus polymerase chain reaction-positive cases were 63% (95% CI: 55–71%) and 35% (95% CI: 28–42%), respectively. The 3 main antiviral treatment approaches identified were oral antivirals alone, intravenous antivirals alone, and a combination of systemic (oral or intravenous) and intravitreal antivirals. The overall pooled estimated proportions of visual acuity improvement, recurrence, and retinal detachment were 37% (95% CI: 27–47%), 14% (95% CI: 8–21%), and 43% (95% CI: 38–50%), respectively. Patients treated with systemic and intravitreal antivirals showed a trend towards better visual outcomes than those treated with systemic antivirals (oral or intravenous) alone, even though this analysis was not statistically significant (test for subgroup differences P = 0.83).
{"title":"Antiviral treatment for acute retinal necrosis: A systematic review and meta-analysis","authors":"Ikhwanuliman Putera MD , Asri Salima Ridwan MD , Metta Dewi MD , Carlos Cifuentes-González MD , William Rojas-Carabali MD , Ratna Sitompul MD, PhD , Lukman Edwar MD, PhD , Made Susiyanti MD, PhD , Yulia Aziza MD, PhD , Carlos Pavesio MD, PhD , Soon-Phaik Chee MD , Padmamalini Mahendradas DO, DNB , Jyotirmay Biswas MS , John H. Kempen MD, MPH, PhD, MHS , Vishali Gupta MD , Alejandra de-la-Torre MD, PhD , Rina La Distia Nora MD, PhD , Rupesh Agrawal MD, FRCS","doi":"10.1016/j.survophthal.2023.09.004","DOIUrl":"10.1016/j.survophthal.2023.09.004","url":null,"abstract":"<div><p>Acute retinal necrosis is a progressive intraocular inflammatory syndrome characterized by diffuse necrotizing retinitis that can lead to a poor visual outcome, mainly from retinal detachment. The antiviral treatment approach for acute retinal necrosis varies as there are no established guidelines. We summarize the outcomes of acute retinal necrosis with available antiviral treatments. Electronic searches were conducted in PubMed/MEDLINE, EMBASE, Scopus, and Google Scholar for interventional and observational studies. Meta-analysis was performed to evaluate the pooled proportion of the predefined selected outcomes. This study was registered in PROSPERO (CRD42022320987). Thirty-four studies with a total of 963 participants and 1,090 eyes were included in the final analysis. The estimated varicella-zoster virus and herpes simplex virus polymerase chain reaction-positive cases were 63% (95% CI: 55–71%) and 35% (95% CI: 28–42%), respectively. The 3 main antiviral treatment approaches identified were oral antivirals alone, intravenous antivirals alone, and a combination of systemic (oral or intravenous) and intravitreal antivirals. The overall pooled estimated proportions of visual acuity improvement, recurrence, and retinal detachment were 37% (95% CI: 27–47%), 14% (95% CI: 8–21%), and 43% (95% CI: 38–50%), respectively. Patients treated with systemic and intravitreal antivirals showed a trend towards better visual outcomes than those treated with systemic antivirals (oral or intravenous) alone, even though this analysis was not statistically significant (test for subgroup differences P = 0.83).</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0039625723001261/pdfft?md5=afc1fda72345e840a2da6c94b082183a&pid=1-s2.0-S0039625723001261-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41103237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-15DOI: 10.1016/j.survophthal.2023.09.001
Alison Choi BS , Baraa S. Nawash BA , Katherine Du BS , Joshua Ong MD , Jay Chhablani MD
Neovascular age-related macular degeneration is the advanced and irreversible stage of age-related macular degeneration, the leading cause of severe vision loss in older adults. While anti-vascular endothelial growth factor injections have been shown to preserve or improve vision quality in eyes with neovascular age-related macular degeneration, the treatment regimen can be demanding of patients and caregivers, leading to lower rates of adherence. Therefore, it is crucial that disparities and obstacles in neovascular age-related macular degeneration care are identified to improve access to treatment. Review of the current literature revealed 7 major categories of barriers: travel burden, psychological barriers, financial burden and socioeconomic status, treatment regimen, other comorbidities, provider-level barriers, and system-level barriers. We provide an overview of the major barriers to neovascular age-related macular degeneration care that have been reported, as well as gaps in research that need to be investigated further.
{"title":"Barriers to care in neovascular age-related macular degeneration: Current understanding, developments, and future directions","authors":"Alison Choi BS , Baraa S. Nawash BA , Katherine Du BS , Joshua Ong MD , Jay Chhablani MD","doi":"10.1016/j.survophthal.2023.09.001","DOIUrl":"10.1016/j.survophthal.2023.09.001","url":null,"abstract":"<div><p>Neovascular age-related macular degeneration is the advanced and irreversible stage of age-related macular degeneration, the leading cause of severe vision loss<span><span> in older adults. While anti-vascular endothelial growth factor injections have been shown to preserve or improve vision quality in eyes with neovascular age-related macular degeneration, the treatment regimen can be demanding of patients and caregivers, leading to lower rates of adherence. Therefore, it is crucial that </span>disparities and obstacles in neovascular age-related macular degeneration care are identified to improve access to treatment. Review of the current literature revealed 7 major categories of barriers: travel burden, psychological barriers, financial burden and socioeconomic status, treatment regimen, other comorbidities, provider-level barriers, and system-level barriers. We provide an overview of the major barriers to neovascular age-related macular degeneration care that have been reported, as well as gaps in research that need to be investigated further.</span></p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10618388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1016/j.survophthal.2023.05.002
Francesco Pellegrini MD , Maria Basciu MD , Julie Falardeau MD
An otherwise asymptomatic 67-year-old man presented to his ophthalmologist complaining of acute painless “dark area on the right.” Visual acuity was preserved, and a single cotton-wool spot was noted in each retina. An inferior right quadrantanopia was evident on automated visual fields, and computerized tomography of the brain confirmed a left occipital stroke. Acute phase markers were elevated, and temporal artery biopsy was consistent with a diagnosis of giant cell arteritis. Isolated retinal cotton wool spots, even in the absence of systemic signs and symptoms, may be suggestive of giant cell arteritis.
{"title":"Pole to pole","authors":"Francesco Pellegrini MD , Maria Basciu MD , Julie Falardeau MD","doi":"10.1016/j.survophthal.2023.05.002","DOIUrl":"10.1016/j.survophthal.2023.05.002","url":null,"abstract":"<div><p><span>An otherwise asymptomatic 67-year-old man presented to his ophthalmologist complaining of acute painless “dark area on the right.” Visual acuity was preserved, and a single cotton-wool spot was noted in each retina. An inferior right </span>quadrantanopia<span><span> was evident on automated visual fields, and computerized tomography of the brain confirmed a left occipital stroke. Acute phase markers were elevated, and temporal </span>artery biopsy<span> was consistent with a diagnosis of giant cell arteritis. Isolated retinal cotton wool spots, even in the absence of systemic signs and symptoms, may be suggestive of giant cell arteritis.</span></span></p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10355957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}